Q-omics provides the consensus-scored CCT6A profile across patient tissues and cancer cell-line models. CCT6A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CCT6A is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, CCT6A protein abundance shows 28,976 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, HNSC, and PDAC as cancer lineages where CCT6A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCT6A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCT6A survival associations across molecular data types. CCT6A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCT6A RNA expression–survival associations across cancer types. High CCT6A expression shows unfavorable associations in MESO, HNSC, ACC, LIHC, KIRP and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CCT6A RNA expression.
This table summarizes CCT6A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CCT6A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCT6A shows higher tumor expression in HNSC, COAD, LUAD, BLCA, KIRP and LIHC. The HNSC box plot shows higher CCT6A RNA expression in tumor versus normal tissue (log2 FC = +1.429, t-test p < 0.001).
This table shows molecular features associated with CCT6A in patient tissues and cancer cell lines. In patient samples, CCT6A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCT6A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
